查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594085

轉移性乳癌治療市場：按治療類型、最終用戶分類 - 全球預測 2025-2030

Metastatic Breast Cancer Treatment Market by Treatment Type (Biologic Targeted Therapy, Breast Surgery, Chemotherapy), End User (Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

轉移性乳癌治療市場2023年估值為216.6億美元，預計到2024年將達到242.9億美元，複合年成長率為12.20%，預計到2030年將達到485.3億美元。

轉移性乳癌治療涉及一種綜合方法，針對已從乳房擴散到身體其他部位的癌症。由於轉移性癌症的複雜性及其對標準治療方法的抵抗力，該領域最需要有效的治療。這些治療方法包括化療、荷爾蒙療法、標靶治療和免疫治療，主要最終用戶是醫院、癌症治療中心和研究機構。市場成長主要是由個人化醫療的進步、乳癌盛行率的增加以及研發方面的大量投資所推動的。精準醫學的出現代表了一個重大的成長機會，它根據基因理解來客製化治療方法。製藥公司和研究機構之間的合作也正在推動創新治療方法和突破。然而，該市場面臨治療成本高、現有治療方法相關的副作用、監管挑戰以及新興地區的經濟負擔問題等限制。新藥嚴格的核准程序也增加了複雜性並減緩了市場成長。為了緩解這些挑戰並利用目前的商機，技術創新的最佳領域包括開發毒性較小的療法、增強藥物輸送系統以及探索聯合治療以提高療效。對生物標記和基因組研究的關注將提供對患者特異性治療的更深入的了解，並提高治療結果的效率。另一方面，增加對生技新興企業的創業投資可以加速創新。市場動態是動態的，高度依賴技術進步和科學研究。相關人員應監控正在進行的臨床試驗並形成策略聯盟，以利用尖端解決方案實現永續成長。這些領域的策略考量指南公司在競爭格局中預測挑戰並最大限度地發揮市場潛力。

主要市場統計
基準年[2023] 216.6億美元
預測年份 [2024] 242.9億美元
預測年份 [2030] 485.3億美元
複合年成長率（%） 12.20%

市場動態：快速發展的轉移性乳癌治療市場的關鍵市場洞察

供應和需求的動態交互作用正在改變轉移性乳癌治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 乳癌患者增加
    • 提高大眾對轉移性乳癌治療的認知
    • 對電離輻射和紫外線輻射的開放性
  • 市場限制因素
    • 轉移性乳癌的治療費用昂貴
  • 市場機會
    • 癌症治療領域的堅實技術進步
    • 轉移性乳癌治療的持續研究和開發
  • 市場挑戰
    • 與治療相關的副作用

波特五力：開拓轉移性乳癌治療市場的策略工具

波特的五力框架是了解轉移性乳癌治療市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解轉移性乳癌治療市場的外部影響

外部宏觀環境因素在塑造轉移性乳癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解轉移性乳癌治療市場的競爭格局

轉移性乳癌治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣轉移性乳癌治療市場供應商的績效評估

FPNV定位矩陣是評估轉移性乳癌治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪轉移性乳癌治療市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對轉移性乳癌治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 乳癌患者增加
      • 提高大眾對轉移性乳癌治療的認知
      • 對電離輻射和紫外線輻射的開放性
    • 抑制因素
      • 轉移性乳癌的治療費用
    • 機會
      • 癌症治療領域的強大技術進步
      • 轉移性乳癌治療的持續研究和開發
    • 任務
      • 與治療相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的轉移性乳癌治療市場

  • 生物標的治療
  • 乳房手術
  • 化療
  • 荷爾蒙療法
  • 放射治療

第7章轉移性乳癌治療市場：依最終用戶分類

  • 診所
  • 醫院

第8章美洲轉移性乳癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區轉移性乳癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲轉移性乳癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-0363DFE03696

The Metastatic Breast Cancer Treatment Market was valued at USD 21.66 billion in 2023, expected to reach USD 24.29 billion in 2024, and is projected to grow at a CAGR of 12.20%, to USD 48.53 billion by 2030.

Metastatic breast cancer treatment involves a comprehensive approach targeting cancer that has spread beyond the breast to other parts of the body. The necessity for effective treatments in this area is paramount due to the complex nature of metastatic cancer and its resistance to standard therapies. Applications of these treatments range from chemotherapy, hormone therapy, targeted therapy, and immunotherapy, with the primary end-users being hospitals, cancer treatment centers, and research institutes. Market growth is significantly influenced by advancements in personalized medicine, increasing prevalence of breast cancer, and substantial investments in R&D. The emergence of precision medicine, which tailors treatment based on genetic understanding, presents a significant opportunity for growth. Collaborations between pharmaceutical companies and research institutions are also fostering innovative therapies and breakthroughs. However, the market faces limitations such as high treatment costs, side effects associated with existing therapies, regulatory challenges, and affordability issues in developing regions. The rigorous approval processes for new drugs add another layer of complexity, slowing the market growth. To mitigate these challenges and capitalize on the current opportunities, the best areas for innovation include the development of less-toxic therapeutic agents, enhancement of drug delivery systems, and the exploration of combination therapies that improve efficacy. A focus on biomarkers and genomic studies can provide deeper insights into patient-specific treatments, raising the efficiency of therapeutic outcomes. Meanwhile, an increasing amount of venture capital in biotech startups could accelerate innovation. The nature of the metastatic breast cancer treatment market is dynamic and heavily reliant on technological advancements and scientific research. Stakeholders should monitor ongoing clinical trials and engage in strategic alliances to leverage cutting-edge solutions for sustainable growth. Strategic insights into these areas can guide companies to both anticipate challenges and maximize their market potential in a competitive landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 21.66 billion
Estimated Year [2024] USD 24.29 billion
Forecast Year [2030] USD 48.53 billion
CAGR (%) 12.20%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Metastatic Breast Cancer Treatment Market

The Metastatic Breast Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing cases of breast cancers
    • Rise in awareness among people for metastatic breast cancer treatment
    • Openness to ionizing and ultraviolet radiation
  • Market Restraints
    • Costly procedures of metastatic breast cancer treatments
  • Market Opportunities
    • Robust technological advancement in the cancer treatments
    • Ongoing research and development in the metastatic breast cancer treatment
  • Market Challenges
    • Side effect associated with the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Metastatic Breast Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Metastatic Breast Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Metastatic Breast Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Metastatic Breast Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Metastatic Breast Cancer Treatment Market

A detailed market share analysis in the Metastatic Breast Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Metastatic Breast Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Metastatic Breast Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Metastatic Breast Cancer Treatment Market

A strategic analysis of the Metastatic Breast Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Metastatic Breast Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Bayer AG, Biocon Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Metastatic Breast Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Biologic Targeted Therapy, Breast Surgery, Chemotherapy, Hormone Therapy, and Radiation Therapy.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cases of breast cancers
      • 5.1.1.2. Rise in awareness among people for metastatic breast cancer treatment
      • 5.1.1.3. Openness to ionizing and ultraviolet radiation
    • 5.1.2. Restraints
      • 5.1.2.1. Costly procedures of metastatic breast cancer treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust technological advancement in the cancer treatments
      • 5.1.3.2. Ongoing research and development in the metastatic breast cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Side effect associated with the treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metastatic Breast Cancer Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Biologic Targeted Therapy
  • 6.3. Breast Surgery
  • 6.4. Chemotherapy
  • 6.5. Hormone Therapy
  • 6.6. Radiation Therapy

7. Metastatic Breast Cancer Treatment Market, by End User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals

8. Americas Metastatic Breast Cancer Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Metastatic Breast Cancer Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Metastatic Breast Cancer Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Biocon Limited
  • 5. Eisai Co., Ltd.
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilead Sciences, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. METASTATIC BREAST CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. METASTATIC BREAST CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. METASTATIC BREAST CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. METASTATIC BREAST CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METASTATIC BREAST CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METASTATIC BREAST CANCER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY BIOLOGIC TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY BREAST SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. METASTATIC BREAST CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. METASTATIC BREAST CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023